10 confirmed partial responses (PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven squamous cell NSCLC patients (ORR 43%) Five confirmed ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent ...

FOSTER CITY, Calif. & MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, ...

In this video series, I show you how to simplify rational complex numbers. We do this by eliminating dividing by an imaginary number. We can either do this by multiplying by i, which produces -1, or ...

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data ...

Here you are in this great, vast wilderness with untold potential for Doing Things — and you can't do a damn one of them. You can ride a horse in a straight line, and then you can do it again. There's ...

What if you could turn a simple sketch on a napkin into a fully functional web design in less than a minute? Below, Teacher’s Tech takes you through how Google Stitch 2.0, powered by the innovative ...

Daiichi Sankyo and Merck & Co. have reported midphase ovarian cancer data, clearing the partners to advance the antibody-drug conjugate into the phase 3 part of the trial. The phase 2 trial tested ...

SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ...

Jiangsu Hengrui Pharmaceuticals’ dealmaking spree rolls on, with a potential $1.1 billion transaction on a rival to AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu being the latest addition.